Move to topTop

Following approval this year by the US Food and Drug Administration (FDA) of the TREO™ Abdominal Aortic Stent-Graft System for the treatment of patients with abdominal aortic aneurysms (AAA), Terumo Aortic announced today the commercial launch of this endovascular device.

One of the first procedures was undertaken by Matt Eagleton MD, Chief of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, US. Dr Eagleton commented, "The procedure was very successful, and the patient is recovering well. As the National Principal Investigator of the IDE study, I was impressed with the performance of the TREO stent-graft system. Stent migration and endoleaks are major concerns in EVAR and as the TREO device offers both suprarenal and infrarenal fixation, distributing the stent-graft fixation in two different anatomical levels, this may work to reduce potential migration as evidenced in the pivotal study. Furthermore, the device design leads to clinically meaningful aneurysm sac shrinkage."

Paul Kuznik, President of Terumo Aortic North America added, "This commercial implant represents a significant milestone for the company as we embark upon delivering the most comprehensive device portfolio within the aortic space."

TREO received CE Mark approval in 2015 and is integral to Terumo Aortic's market-leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.